Nkarta, Inc. — Q1 2024 Form 10-Q
Reporting period: Three months ended March 31, 2024. Nkarta is a clinical-stage biopharmaceutical company developing engineered, off-the-shelf natural killer (NK) cell therapies. It has no approved products and has not generated product-sales revenue.
Financial performance and position
| Metric | Q1 2024 | Q1 2023 |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $25.2 million | $26.1 million |
| General and administrative expense | $7.5 million | $8.2 million |
| Total operating expenses / operating loss | $32.8 million | $34.3 million |
| Interest and other income, net | $3.2 million | $3.5 million |
| Net loss | $29.5 million | $30.8 million |
| Net loss per share, basic and diluted | $0.58 | $0.63 |
| Net cash used in operating activities | $28.5 million | $20.8 million |
At March 31, 2024, cash and cash equivalents were $250.3 million, short- and long-term investments totaled $196.9 million, and restricted cash was $2.7 million, for combined cash, restricted cash and investments of approximately $450.0 million. Current assets were $442.8 million and current liabilities were $22.2 million. Total liabilities were $103.3 million, including $87.2 million of operating lease liabilities; the filing reports no debt balance. Accumulated deficit was $465.0 million. Operating margins are not meaningful given the absence of revenue.
Changes versus the prior comparable period
- Net loss narrowed by $1.3 million, as operating expenses fell by $1.6 million; lower interest income partly offset the improvement.
- R&D expense declined by $0.9 million. The company cited lower program costs, including reduced NKX101 manufacturing and materials spending, offset by higher internal research, laboratory and facilities costs.
- G&A expense fell by $0.7 million, primarily reflecting lower personnel costs after the October 2023 reduction in force.
- Operating cash use increased by $7.7 million year over year. Q1 2023 cash flows benefited from tenant-improvement allowance receipts; Q1 2024 included no comparable receipt.
Funding, outlook, and material developments
- On March 27, 2024, Nkarta completed an underwritten offering of 21.01 million common shares and pre-funded warrants for up to 3.00 million additional shares. The offering generated $240.1 million gross proceeds and approximately $225.1 million net proceeds after discounts, commissions and expenses. The warrants are exercisable for $0.0001 per share and none had been exercised at quarter-end.
- Management said available cash, cash equivalents and investments should fund operations for at least 12 months from the filing date. This estimate is subject to uncertainty; the company expects continuing losses and says additional capital will be needed to support its longer-term plans.
- Management expects R&D expense to increase substantially as development advances, including planned NKX019 clinical work in lupus nephritis (LN), and expects G&A costs to rise over time in support of development and public-company requirements.
- NKX019 is the lead program. A Phase 1 trial for refractory LN was planned, with first-patient dosing targeted for the first half of 2024. A Phase 1 study in B-cell malignancies continues, but prior dose-expansion results did not meet expectations; a compressed dosing schedule is being evaluated.
- Nkarta closed enrollment and deprioritized NKX101 after interim response data were lower than observed in the initial patients. Further development is uncertain and would require reassessment of trial design, dosing and manufacturing.
- Principal risks include clinical and regulatory uncertainty, patient enrollment, manufacturing scale-up and sole-supplier dependence for certain manufacturing steps, competition, intellectual-property exposure, and the possibility of needing additional capital on unfavorable terms or not obtaining it.
- The company reported no material pending legal claims and no loss contingency accrual. Disclosure controls and procedures were assessed as effective at a reasonable assurance level; no material change in internal control over financial reporting was reported for the quarter.
Important facts for investors to verify
- Whether NKX019’s LN trial began dosing on the stated timetable, and what subsequent safety, enrollment and efficacy updates show.
- Whether the compressed-schedule NKX019 cancer cohort produces results that support continued investment, given earlier expansion-cohort results.
- Whether management’s cash-runway estimate remains valid as clinical, manufacturing and facility costs evolve; track operating cash use and any new financing.
- How the March offering and pre-funded warrants affect share count and potential dilution. The filing reports 70,453,561 common shares at March 31 and 70,467,620 outstanding at May 6; warrants could add up to 3,000,031 shares.
- Progress in qualifying commercial-scale manufacturing capacity and mitigating reliance on the Miltenyi CliniMACS Plus system and other critical suppliers.